Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03976401 · ClinicalTrials.gov registry record · Phase 2
A Study of Efruxifermin in Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)
A Phase 2 study, sponsored by Akero Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 110
- Enrollment target
NCT03976401 is a Phase 2 study that has completed, run by Akero Therapeutics. The registered enrollment target is 110 participants.
The verdict
NCT03976401, a Phase 2 study, has completed, sponsored by Akero Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 110 participants
- Enrollment target
Study Summary
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study administered for 16 weeks in subjects with biopsy proven F1 - F4 NASH.
Interventions
- DRUG Placebo
- DRUG EFX
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2019-05-28 |
| Est. Completion | 2022-01-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03976401
The ClinicalTrials.gov registry entry for NCT03976401 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Akero Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03976401 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03976401 about?
NCT03976401 is a clinical study titled "A Study of Efruxifermin in Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)". This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study administered for 16 weeks in subjects with biopsy proven F1 - F4 NASH.
What is the current status of trial NCT03976401?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 110 participants. The study started on 2019-05-28. Estimated completion is 2022-01-10.
What interventions are being tested in trial NCT03976401?
The interventions under investigation include: Placebo (DRUG), EFX (DRUG).
Who is sponsoring clinical trial NCT03976401?
This trial is sponsored by Akero Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.